ClinicalTrials.gg
CompletedNCT03145064Updated Oct 26, 2024Results posted

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

A Phase 2 interventional study of Zanubrutinib in Diffuse Large B-cell Lymphoma, sponsored by BeiGene. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse — 19 open to participants now, 23 under way, 1 of them phase 3. zanubrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
11th of 30
41 · median 39
Started
2017
the only one that year
Phase 2
26 of 30
17 open now
Registered
1st of 30
by date
Lead sponsor
4 of 30
BeiGene

Among the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 26 in phase 2, and was the 1st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

19 of the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.

Read the detailed description

This is a single-arm, multicenter, open-label Phase 2 study to evaluate efficacy, safety, tolerability of BGB-3111 (zanubrutinib) in participants with relapsed/refractory non-germinal center B-cell (GCB) type diffuse large B-cell lymphoma (DLBCL).

The study will enroll approximately 40 participants treated with zanubrutinib (160 milligrams [mg]) twice daily (BID). All participants in the study were treated until disease progression, unacceptable toxicity, death, withdrawal of consent, or the study was terminated by the sponsor for final analysis. At the time of final analysis, participants who remained on treatment were considered for participation in the extension study when eligible. A treatment cycle consisted of 28 days.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma

Keywords

  • Relapsed/refractory non-GCB type
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed non-germinal center DLBCL, by immunohistochemistry using the Hans algorithm:

    1. Cluster of differentiation 10 (CD10)- and B-cell lymphoma 6 protein (BCL6)-,
    2. CD10-, BCL6+, but maximal unique match+
  2. Men and women ≥ 18 years of age.
  3. performance status of 0-2.
  4. was defined as at least 1 lymph node > 1.5 centimeters in longest diameter and measurable in 2 perpendicular dimensions.
  5. All participants must have provided fresh tumor or recent tumor tissue samples (within 2 years of study entry [ form signed]).
  6. Received at least one prior therapy for DLBCL that included anthracycline-based chemotherapy.
  7. Participant not eligible for or refused intensive chemotherapy and hematopoietic stem cell transplant.
  8. Documented failure to achieve at least partial response with, or documented disease progression after response to, the most recent treatment regimen.
  9. Neutrophils ≥ 1 x 10\^9/liter (L) independent of growth factor support within 7 days of study entry.
  10. ≥ 75 x 10\^9/L, independent of growth factor support or transfusion within 7 days of study entry.
  11. of ≥ 30 milliliters/minute (as estimated by the Cockcroft-Gault equation or estimated ).
  12. and alanine aminotransferase ≤ 2.5 x (ULN).
  13. ≤ 2 x ULN (unless documented Gilbert's syndrome), then up to 5 x ULN allowed.
  14. Independent of erythropoietin support or transfusion within 7 days of first dose of study drug.
  15. ≤ 1.5 and activated partial thromboplastin time ≤ 1.5 x ULN.
  16. Participants may be enrolled who after stem cell transplant if they are at least 6 months after transplant, participants should have had no active infections (that is, fungal or viral).
  17. Females of must have agreed to use highly effective forms of throughout the course of the study and at least up to 90 days after last dose of study drug. Highly effective forms of birth control were defined as abstinence, hysterectomy, bilateral oophorectomy with no menstrual bleeding for up to 6 months, intrauterine contraception, hormonal methods such as contraceptive injection, oral contraceptive. Males must have undergone sterilization-vasectomy, or utilized a barrier method where the female partner utilized the effective forms of birth control noted above.
  18. of > 3 months.
  19. Able to provide written informed consent and could understand and comply with the requirements of the study.

Key Exclusion Criteria:

  1. Current or history of central nervous system lymphoma.
  2. Prior exposure to a BTK inhibitor.
  3. Prior (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, or radiation therapy within 3 weeks, or antibody-based therapies or Chinese anti-cancer herbal therapies within 4 weeks of the start of study drug.
  4. Major surgery within 4 weeks of screening.
  5. Toxicity of ≥ Grade 2 from prior anti-cancer therapy (except for alopecia, [ANC]) and platelets. For ANC and platelets, please follow inclusion criteria #9 [neutrophils] and #10 [platelets]).
  6. History of other active within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.
  7. Currently active cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease as defined by the Functional Classification, or history of myocardial infarction within 6 months of screening. is lower than 50% measured by echocardiography.
  8. (Fridericia's correction) > 450 milliseconds or other significant abnormalities including second degree atrioventricular (AV) block Type II, or third-degree AV block.
  9. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  10. Uncontrolled systemic infection or infection requiring parenteral anti-microbial therapy.
  11. Known , or active or infection (detected positive by polymerase chain reaction).
  12. Pregnant or lactating women.
  13. Any life-threatening illness, medical condition or organ system dysfunction, which, in the investigator's opinion, could compromise the participant's safety, or put the study at risk.
  14. On medications that were strong cytochrome P450 (CYP), family 3, subfamily A () inhibitors or CYP3A inducers.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Participants received zanubrutinib BID.

    Drug: Zanubrutinib

Interventions

  • Administered at a dose of 160 mg BID orally.

    Also known as: BGB-3111, BRUKINSA

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate was defined as the percentage of participants achieving either a partial response (PR) or complete response (CR) as determined by investigator according to the 2014 modification of the International Working Group (IWG) in Non-Hodgkin's lymphoma (NHL) Criteria.

    Time frame: Up to approximately 23 months

Secondary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from first dose of zanubrutinib until first documentation of progression (by IWG on NHL criteria) or death, whichever occurred first.

    Time frame: Up to 3 years and 2 months

  2. Duration Of Response

    Duration of response was defined as the time from the date that the response criteria were first met to the date that progressive disease was objectively documented or death, whichever occurred first. Duration of response was summarized for responders (with a best overall response of CR or PR) only.

    Time frame: Up to 3 years and 2 months

  3. Time To Response

    Time to response was defined as the time from the first dose of zanubrutinib to the documentation of first response. Time to response was summarized for responders (with a best overall response of CR or PR) only.

    Time frame: Up to 3 years and 2 months

  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A treatment-emergent adverse event was defined as an adverse event that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up Visit) or initiation of new anticancer therapy, whichever occurred first.

    Time frame: From the time of informed consent to 30 days after the last dose of study drug (approximately Up to 3 years and 2 months)

Other outcomes

  1. Overall Survival

    Overall survival was defined as the time from first dose of zanubrutinib until death due to any cause.

    Time frame: Up to 3 years and 2 months

07

Results

Posted Nov 8, 2021

Participant flow

This study was conducted at 11 centers in China, all of which enrolled participants. The first participant was dosed on 30 June 2017. Since the primary and secondary objectives were met and the analysis was complete, the sponsor ended the study on 03 September 2020 (Last patient last visit). As of the final database lock (15 October 2020), 41 participants were enrolled and treated with zanubrutinib.

Participant flow — Overall Study
MilestoneZanubrutinib
Started41
Received at least 1 dose of study drug41
Completed0
Not completed41
Withdrew: Death24
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject6
Withdrew: Study ended by sponsor once primary/ secondary analysis was complete and participants discontinued4
Withdrew: Other: transferred to long term extension (lte) study bgb-3111-lte1 (nct04170283)4

Outcome measures

PrimaryOverall Response Rate

Overall response rate was defined as the percentage of participants achieving either a partial response (PR) or complete response (CR) as determined by investigator according to the 2014 modification of the International Working Group (IWG) in Non-Hodgkin's lymphoma (NHL) Criteria.

Time frame:
Up to approximately 23 months
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsZanubrutinib
Overall Response Rate29.3 (16.13 to 45.54)
SecondaryProgression-free Survival

Progression-free survival was defined as the time from first dose of zanubrutinib until first documentation of progression (by IWG on NHL criteria) or death, whichever occurred first.

Time frame:
Up to 3 years and 2 months
Reported as:
Median · months
Progression-free Survival
monthsZanubrutinib
Progression-free Survival2.8 (2.56 to 5.45)
SecondaryDuration Of Response

Duration of response was defined as the time from the date that the response criteria were first met to the date that progressive disease was objectively documented or death, whichever occurred first. Duration of response was summarized for responders (with a best overall response of CR or PR) only.

Time frame:
Up to 3 years and 2 months
Reported as:
Median · months
Duration Of Response
monthsZanubrutinib
Duration Of Response4.5 (2.14 to NA)
SecondaryTime To Response

Time to response was defined as the time from the first dose of zanubrutinib to the documentation of first response. Time to response was summarized for responders (with a best overall response of CR or PR) only.

Time frame:
Up to 3 years and 2 months
Reported as:
Median · months
Time To Response
monthsZanubrutinib
Time To Response2.83 (2.6 to 3.2)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

A treatment-emergent adverse event was defined as an adverse event that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up Visit) or initiation of new anticancer therapy, whichever occurred first.

Time frame:
From the time of informed consent to 30 days after the last dose of study drug (approximately Up to 3 years and 2 months)
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsZanubrutinib
Participants with at least1 TEAE36
Serious TEAE12
TEAE leading to treatment discontinuation4
Other pre-specifiedOverall Survival

Overall survival was defined as the time from first dose of zanubrutinib until death due to any cause.

Time frame:
Up to 3 years and 2 months
Reported as:
Median · months
Overall Survival
monthsZanubrutinib
Overall Survival8.4 (4.8 to NA)

Adverse events

Collected over From the time of informed consent to 30 days after the last dose of study drug (approximately up to 3 years and 2 months).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib24/41 (58.5%)12/41 (29.3%)34/41 (82.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventZanubrutinib
PneumoniaInfections and infestations3/41
DeathGeneral disorders2/41
Abdominal infectionInfections and infestations1/41
Herpes zosterInfections and infestations1/41
Otitis media chronicInfections and infestations1/41
Urinary tract infectionInfections and infestations1/41
Gait inabilityGeneral disorders1/41
Abdominal painGastrointestinal disorders1/41
Intestinal obstructionGastrointestinal disorders1/41
Sudden hearing lossEar and labyrinth disorders1/41
Most frequent other events
Showing 10 of 36
Most frequent other events
EventZanubrutinib
Neutrophil count decreasedInvestigations9/41
HypokalaemiaMetabolism and nutrition disorders7/41
Platelet count decreasedInvestigations5/41
Blood creatinine increasedInvestigations4/41
Lymphocyte count decreasedInvestigations4/41
White blood cell count decreasedInvestigations4/41
ConstipationGastrointestinal disorders4/41
DiarrhoeaGastrointestinal disorders4/41
Urinary tract infectionInfections and infestations4/41
CoughRespiratory, thoracic and mediastinal disorders4/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zanubrutinib
Mean57.2 ± 12.45
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib
Female16
Male25
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zanubrutinib
American Indian or Alaska Native0
Asian41
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(Participants)Zanubrutinib
Grade 010
Grade 127
Grade 24
Hepatitis B Core Antibody
Hepatitis B Core Antibody(Participants)Zanubrutinib
Positive13
Negative28
08

Study locations

11 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Soochow University Branch Shizi
    Suzhou, Jiangsu 215006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200025, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin 300020, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Yang H, Xiang B, Song Y, Zhang H, Zhao W, Zou D, Lv F, Bai O, Liu A, Li C, Tan Z, Wang W, Gui H, Novotny W, Huang J, Li Y. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study. American Society of Clinical Oncology. 2020

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in May 2019, 22 months.

Results were first posted in Nov 2021, 2 years 5 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 22 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2017
First posted
May 9, 2017
StartActual
Jun 30, 2017
Primary completionActual
May 24, 2019
CompletionActual
Sep 3, 2020
Results first posted
Nov 8, 2021
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03145064
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
May 9, 2017
Start date
Jun 30, 2017
Primary completion
May 24, 2019
Completion
Sep 3, 2020
Results posted
Nov 8, 2021
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion